Literature DB >> 2706134

The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children.

J Treuner1, J Suder, M Keim, P Kaatsch, D Niethammer.   

Abstract

The relation between the initial tumour regression produced by chemotherapy and the later event-free survival was studied in a prospective multicentre study on soft-tissue sarcomas in children. The event-free survival rate in patients with complete remission after seven weeks of chemotherapy was 95%; in patients with incomplete tumour reduction of greater than 2/3, 61%; and in patients with tumour reduction of less than 2/3 but greater than 1/3, 31%. Patients with partial remission at week 7, who achieved complete remission by week 16 after additional chemotherapy had an event-free survival rate of 64%. A multivariate analysis suggested that the response per unit of time was an important prognostic factor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706134     DOI: 10.3109/02841868909111184

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group.

Authors:  Beverly Raney; Julie Stoner; James Anderson; Richard Andrassy; Carola Arndt; Ken Brown; William Crist; Harold Maurer; Stephen Qualman; Moody Wharam; Eugene Wiener; William Meyer; Andrea Hayes-Jordan
Journal:  J Pediatr Surg       Date:  2010-11       Impact factor: 2.545

2.  The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.

Authors:  K Cam; A Yildirim; H Ozveri; L Turkeri; A Akdas
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 3.  The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

Authors:  Frederick B Ruymann
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.